The Bayer stock gained around 3% on Monday, September 14, and approached the EUR 50 mark again ahead of a key US court hearing related to the Roundup litigation.
The hearing in Missouri begins today and addresses the final approval of a class action settlement for Roundup lawsuits. Bayer has indicated that the court’s decision is expected at a later date and not immediately following the hearing.
For Bayer, which remains a position within the UMBRELLA Strategy, one of the company’s most important remaining legal risks thus moves back into focus.
Roundup Litigation Remains in Focus
The Roundup litigation has been a significant uncertainty factor for Bayer for several years. The current proceedings in Missouri are therefore particularly relevant, as the hearing addresses the proposed settlement framework intended to cover a substantial portion of the outstanding litigation.
The market reacted positively ahead of the hearing. The Bayer stock stood at EUR 49.36 in late Monday morning trading, up around 2.5%.
The hearing itself does not yet eliminate the legal uncertainty. The next important step will be the court’s decision on whether the settlement receives final approval.
Analyst Consensus
| Analyst Consensus | Current |
|---|---|
| Recommendation | ADD |
| Number of Analysts | 18 |
| Average Price Target | approx. EUR 58 |
| Upside Potential | +21% |
| Highest Price Target | EUR 70 |
| Lowest Price Target | EUR 46 |
Analyst sentiment toward Bayer has recently developed more constructively.
Recent adjustments also point in a more positive direction. Barclays raised its price target to EUR 70 on September 8 and confirmed its “Overweight” rating, while the Deutsche Bank maintained its buy recommendation with a price target of EUR 60 on September 10.
Technical Picture: Bayer Tests Resistance at EUR 50
The current chart shows that Bayer stock continues to consolidate after the strong upward movement in June and July.
The RSI (14) stands at around 58, signaling constructive momentum without an overbought signal. The MACD momentum is near neutral and reflects the recent consolidation phase.
Key Takeaway
Bayer is approaching a key technical resistance zone while Roundup litigation enters another critical phase.
